Ikena Oncology Inc Cash Flow Conversion Efficiency
Ikena Oncology Inc cash flow conversion efficiency. Based on the latest financial reports, Ikena Oncology Inc (IKNA) has a cash flow conversion efficiency ratio of -0.030x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($115.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ikena Oncology Inc (2018–2024)
Cash flow conversion efficiency of Ikena Oncology Inc from 2018 to 2024. This chart illustrates how Ikena Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ikena Oncology Inc (IKNA) share price today for real-time trading data and today's change.
Ikena Oncology Inc Cash Flow Conversion Ratio Explained
Ikena Oncology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ikena Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ikena Oncology Inc ranked by their cash flow conversion efficiency. Also see Ikena Oncology Inc (IKNA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Herige SA
PA:ALHRG
|
0.119x |
|
DASAN Networks Inc
KQ:039560
|
0.044x |
|
Sangsangin Co. Ltd
KQ:038540
|
1.338x |
|
Skolon AB
ST:SKOLON
|
-2.083x |
|
Citizens Holding Company
NASDAQ:CIZN
|
0.016x |
|
TEAM INC. DL-30
F:T9CA
|
-0.685x |
|
Yong Pyong Resort Corp
KO:070960
|
0.006x |
|
PYRAMID TECHNOPLAST ORD (BSE)
NSE:PYRAMID
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Ikena Oncology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Ikena Oncology Inc from 2018 to 2024. Review Ikena Oncology Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more